Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

GSK239512 DDI Study

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: January 4, 2013
Last updated: May 30, 2013
Last verified: May 2013
The study will determine the effect of 400 mg once daily of ketoconazole at steady state on the pharmacokinetics of a single oral dose of GSK239512 in young healthy volunteers. Ketoconazole is a strong inhibitor of CYP3A4, which is involved in metabolism of drugs. A two-cohort design will be applied with cohort 1 aimed at providing a first estimate of the interaction potential of GSK239512 and ketoconazole in terms of pharmacokinetic parameters in a small number of subjects. Data from Cohort 1 will inform the decision of which dose to use in Cohort 2, in which a larger number of subjects will be exposed to GSK239512 without and with ketoconazole. The target maximum exposure is aimed to be similar to the exposure by a single dose of 80 mcg of GSK239512 without CYP3A4 inhibition. In summary, the results from this study will help to estimate the maximum increase in exposure of GSK239512 during concomitant use of strong CYP3A4 inhibitors and will help define the subsequent dosing strategy around GSK239512 and co-medications with potential to inhibit CYP3A4.

Condition Intervention Phase
Multiple Sclerosis
Drug: GSK239512
Drug: ketoconazole
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK239512

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • AUC of GSK239512 [ Time Frame: Predose and up to 120 hour post dose of GSK239512 ] [ Designated as safety issue: No ]
  • Cmax of GSK239512 [ Time Frame: Predose and up to 120 hour post dose of GSK239512 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of participants with adverse events as a measure of safety and tolerability [ Time Frame: 15 weeks ] [ Designated as safety issue: No ]

Enrollment: 22
Study Start Date: January 2013
Study Completion Date: May 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Session 1 or Session 2
Single dose sessions without ketoconazole co-administration
Drug: GSK239512
H3 receptor antagonist, potential victim of drug-drug interaction
Active Comparator: Co-dose Session
Single dose session with ketoconazole co-administration
Drug: GSK239512
H3 receptor antagonist, potential victim of drug-drug interaction
Drug: ketoconazole
CYP3A4 inhibitor, potential perpetrator of drug-drug interaction


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Male between 18 and 45 years of age inclusive, at the time of signing the informed consent.
  2. Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  3. ALT, alkaline phosphatase and bilirubin < or = 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  4. QTcF < 450 msec.
  5. Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until 1 month post-last dose of GSK239512.
  6. Body weight > 50 kg, and body mass index (BMI) between 19.0 - 29.9 kg/m2 inclusive.
  7. Capable of giving informed consent and can comply with the study requirements and timetable.

Exclusion Criteria:

  1. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
  2. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  3. A positive pre-study drug/alcohol screen.
  4. A positive test for Human Immunodeficiency Virus (HIV) antibody.
  5. History of alcohol consumption exceeding, on average, 21 drinks/week for men (1 drink = 100 mL of wine or 240 mL of beer or 30 mL of hard liquor in Australia) within 6 months of the first dose of study medication.
  6. History of smoking cigarettes or using tobacco products or any nicotine-containing products (including nicotine patches) within 3 months of screening.
  7. The subject has participated in a clinical trial and has received an investigational product within 30 days or 5 half lives (whichever is longer) prior to the first dosing day in the current study.
  8. Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  9. Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  10. History of sensitivity to ketoconazole, or to the excipients contained in GSK239512 or Nizoral, or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  11. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  12. Unwillingness or inability to follow the procedures outlined in the protocol.
  13. Subject is mentally or legally incapacitated.
  14. Have used the following medications within the last 30 days or 5 half-lives (whichever is longer) prior to screening and are not able to discontinue use throughout participation in the clinical trial:

    • Any CNS stimulants (e.g., modafinil, dexamphetamine, methylphenidate).
    • Known potent P-glycoprotein inhibitors (e.g. itraconazole, ketoconazole, cyclosporin, loperamide, diltiazem, verapamil, spironolactone, quinidine, bepridil, quinine, carvedilol).
    • Known potent inhibitors or inducers of the CYP3A4 enzyme (see Appendix 3).
    • CNS-penetrant antihistamines (e.g. bromopheniramine, chlorpheniramine, clemastine, diphenhydramine, hyrdoxyzine)
    • Any other medicines that are contraindications of Nizoral (see Appendix 4).
  15. Unable to refrain from consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication.
  16. The subject has a history of significant psychiatric illness.
  17. Presence or history of hallucinations that, in the judgement of the investigator, may increase the safety risk to the subject.
  18. At risk of suicide, as indicated by:

    • A documented history of attempted suicide or significant suicidal ideation during the 6 months preceding the screening visit, OR
    • If in the investigator's judgment the subject is at risk of a suicide attempt based on the screen visit assessment, including the C-SSRS.
  19. Diagnosis of any type epilepsy
  20. Night shift workers within 4 weeks of first dosing
  21. Presence of significant and routine sleep disturbance that has a negative impact on quality of life that, in the judgement of the investigator, may increase the risk of tolerability issues during dose escalation.

    • Examples of significant sleep disturbances may be: severe insomnia, nocturnal wandering, confusion, disorientation, agitation, or vivid dreams.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01802931

Australia, New South Wales
GSK Investigational Site
Randwick, New South Wales, Australia, 2031
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT01802931     History of Changes
Other Study ID Numbers: 117016 
Study First Received: January 4, 2013
Last Updated: May 30, 2013
Health Authority: United States: Food and Drug Administration
Australia: Therapeutic Goods Administration

Keywords provided by GlaxoSmithKline:
H3 receptor antagonist
drug-drug interaction

Additional relevant MeSH terms:
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Histamine H3 Antagonists
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents processed this record on October 21, 2016